Tetraphase Pharmaceuticals, Inc.

Amid an ongoing capital crunch, Chinese drug makers pursuing in-licensing models have arrived at a commercialization crossroads. Jump-started by frontrunner Zai Lab Ltd. ’s successful introduction of

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. TiumBio, Hansoh Ink $170m Endometr

The US FDA’s approval of two novel antifungals for women with vulvovaginal candidiasis in a little over a year – plus a significant new claim already under review – gives the common yeast infection a

Innoviva, Inc. continues to branch out from collecting royalties on inhaled respiratory medicines commercialized by GlaxoSmithKline Pharmaceuticals Ltd. to a company also developing and commerciali